Skip to content

Myocardial Perfusion in Type 2 Diabetes

Evaluation of Myocardial Perfusion and Microvascular Reserve in Real-time Utilizing Myocardial Contrast Echocardiography in Type 2 Diabetes.

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01043965
Enrollment
61
Registered
2010-01-07
Start date
2005-08-31
Completion date
2009-08-31
Last updated
2010-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Diabetes Mellitus, Myocardial perfusion imaging, Heart diseases, Echocardiography, Endothelium

Brief summary

The investigators aimed to evaluate microvascular circulation with novel method: real-time myocardial contrast echocardiography in patients with type 2 diabetes and normal coronary arteries. Myocardial blood flow reserve will be determined by quantitative contrast Stress echocardiography. Diabetic individuals will be evaluate in a decompensated state (Phase 1) and after optimization of medical treatment four months later (Phase 2).

Detailed description

Early stages of epicardial atherosclerosis in patients with type 2 diabetes are associated with an impairment in endothelium-dependent dilation of the coronary microvasculature, indicating that the pathophysiological consequences of atherosclerosis may extend into the coronary microcirculation. The investigators will evaluate three parameters of myocardial quantification with contrast Stress echocardiography and correlate with HbA1C levels.

Interventions

DRUGMetformin

Metformin 850mg

Sponsors

Fundação de Amparo à Pesquisa do Estado de São Paulo
CollaboratorOTHER_GOV
University of Sao Paulo General Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Type 2 diabetes mellitus * Normal echocardiogram * Absence of obstructive epicardial coronary disease

Exclusion criteria

* Obstructive coronary disease * Heart valve disease * COPD * Cardiac Arrhythmias * Cardiomyopathy

Design outcomes

Primary

MeasureTime frame
myocardial blood flow velocity, myocardial blood flow reserve3 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026